| Previous Close | 5.68 |
| Open | 5.70 |
| Bid | 5.35 x 1200 |
| Ask | 5.85 x 1800 |
| Day's Range | 5.65 - 5.82 |
| 52 Week Range | 3.35 - 12.57 |
| Volume | 295,112 |
| Avg. Volume | 639,665 |
| Market Cap | 161.296M |
| Beta (5Y Monthly) | 1.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.03 |
| Earnings Date | Feb 24, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.94 |
EMERYVILLE, Calif., Feb. 20, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful.
EMERYVILLE, Calif., Feb. 19, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday,.
Adamas Pharmaceuticals, Inc. (ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules for the treatment of dyskinesia in people with Parkinson's disease (PD) receiving levodopa-based therapy at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress (PAS-MDS), February 14-16, 2020 in Miami, Florida. “The data presented at this year’s MDS-PAS conference build upon the growing evidence that GOCOVRI can help improve good ON time in patients with PD who experience levodopa-induced dyskinesia,” said Jean Hubble, Vice President, Medical Affairs at Adamas.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...
Adamas Pharmaceuticals, Inc. (ADMS) a company dedicated to developing and delivering medicines that make a clinically meaningful difference for people affected by neurological diseases, today announced the publication of final results from a two-year open-label study in Parkinson’s disease (PD) that demonstrated a sustained improvement in levodopa-induced dyskinesia (LID) among patients using GOCOVRI® (amantadine) extended-release capsules. The trial enrolled 223 patients, and results demonstrated that the treatment effect of GOCOVRI on motor complications (dyskinesia and OFF), as measured by the Movement Disorder Society‐Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS), Part IV, was maintained for at least two years.
NEW YORK, NY / ACCESSWIRE / February 10, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered ...
NEW YORK, Feb. 10, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) managed care's acceptance of GOCOVRI; (2) the breadth of insurer coverage for GOCOVRI prescriptions; and (3) the impact of the Company's commercialization efforts.
NEW YORK, NY / ACCESSWIRE / February 9, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
NEW YORK, NY / ACCESSWIRE / February 8, 2020 / Rosen Law Firm reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) between August 8, 2017 and September 30, 2019, inclusive ...
NEW YORK, NY / ACCESSWIRE / February 7, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) managed care's acceptance of GOCOVRI; (2) the breadth of insurer coverage for GOCOVRI prescriptions; and (3) the impact of the Company's commercialization efforts.
NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ:ADMS) ...
NEW YORK, NY / ACCESSWIRE / February 5, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
LOS ANGELES, CA / ACCESSWIRE / February 5, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, has filed a class action lawsuit against Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ:ADMS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2017 and September 30, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020.
NEW YORK, NY / ACCESSWIRE / February 5, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. A class action has commenced on behalf of certain shareholders in Adamas Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" - i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.
NEW YORK, Feb. 05, 2020 -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Adamas Pharmaceuticals, Inc. ("Adamas" or.
NEW YORK, NY / ACCESSWIRE / February 5, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly traded companies. Shareholders ...
NEW YORK, NY / ACCESSWIRE / February 4, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
LOS ANGELES, CA / ACCESSWIRE / February 4, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, has filed a class action lawsuit against Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ:ADMS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2017 and September 30, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020.
NEW YORK, NY / ACCESSWIRE / February 4, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On March 4, 2019, Adamas revised previous prescription growth estimates for GOCOVRI, the Company’s primary product, warned of a continued slowdown in GOCOVRI prescriptions, and refused to predict GOCOVRI’s ability to achieve a sizeable market share.